Advancing Dignity, Health, and Optimism in Connection With Long Acting Injectables
ADHOC-LA is an observational study of people living with HIV who either are taking, or have taken, a long-acting injectable therapy to manage their HIV. Data from this study will be used to research the ways in which HIV impacts the lives of these patients.
‣ Eligibility Criteria:
• Have an HIV-1 infection
• a) Currently take a long-acting injectable therapy for HIV supplied by ViiV as part of a ViiV-sponsored, long-acting injectables therapy trial (LATTE-2, ATLAS-2M, CUSTOMIZE, POLAR, FLAIR, or SOLAR), or
• b) Currently take a long-acting injectable therapy for HIV prescribed by their provider, not in conjunction with a ViiV-sponsored clinical trial, or
• c) No longer taking long-acting injectable therapy for HIV, but previously received three or more injections of long-acting injectable therapy, either:
⁃ Supplied by ViiV as part of a ViiV-sponsored, long-acting injectables therapy trial (LATTE-2, ATLAS-2M, CUSTOMIZE, POLAR, FLAIR, or SOLAR), or
⁃ Prescribed by their provider, unrelated to a ViiV-sponsored clinical trial.
• Age 18 or above
• Have no known acute medical problem requiring immediate inpatient treatment
• Able to read and write in English
• Able and willing to provide online informed consent and to complete the online profile
• Not currently enrolled in another clinical trial in which the participant is receiving a long-acting injectable therapy for HIV.
‣ Participants who meet the eligibility criteria but are still receiving ViiV-supplied drug may enroll in the registry, but will not begin the online questionnaire until they are rolled off of ViiV-supplied long-acting injectable therapy.